Clinical Trial Update: Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3 [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of eliglustat with or without imiglucerase in pediatric Gaucher disease types 1 and 3; the study status is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease Type
• Gaucher Disease Type Iii

Drugs mentioned

• CEREZYME (imiglucerase)
• Cerdelga (Eliglustat)

Snippet

Sponsor: Sanofi | Conditions: Gaucher's Disease Type I, Gaucher's Disease Type III | Phase 3 | Status: COMPLETED